文献速递神经肿瘤小儿神经外科与脑积水

维利帕尼联合放疗及替莫唑胺治疗新诊断弥漫性桥脑胶质瘤的I/II期研究:儿童脑肿瘤联盟研究

A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study.
PubMed 文献 · Neuro Oncol · 2020-01-01

儿童脑肿瘤联盟(PBTC)在66例新诊断弥漫性内生性桥脑胶质瘤(DIPG)患儿中开展维利帕尼联合放疗序贯维利帕尼联合替莫唑胺的I/II期试验,维利帕尼同步放疗的II期推荐剂量为65 mg/m2每日两次,维持期替莫唑胺患者内剂量递增未耐受,因无效提前终止入组,1年总生存率37.2%(SE 7%)、2年5.3%(SE 3%),未优于PBTC历史对照。

要点

  • 维利帕尼同步放疗的II期推荐剂量为65 mg/m2每日两次(周一至周五)。
  • 维持期替莫唑胺患者内剂量递增未耐受。
  • 计划中期分析后因无生存获益且无效停止入组。

核心结论

  • 维利帕尼联合放疗序贯替莫唑胺和维利帕尼方案可耐受,但未改善新诊断DIPG患者的生存。
  • 计划中期分析后结论为该治疗与PBTC历史对照相比未显示生存获益,因无效停止入组。

研究设计与样本

  • 儿童脑肿瘤联盟(PBTC)I/II期试验,纳入新诊断弥漫性内生性桥脑胶质瘤(DIPG)患儿。
  • 共入组66例患者(65例合格)。
  • 放疗期间维利帕尼周一至周五每日两次给药,随后休息4周。
  • 维持期维利帕尼25 mg/m2每日两次联合替莫唑胺135 mg/m2每日一次连用5天,每28天为一周期。
  • 对发生轻微毒性的患者进行替莫唑胺患者内剂量递增探索。

主要发现

  • 维利帕尼同步放疗的II期推荐剂量为65 mg/m2每日两次。
  • 放疗期间维利帕尼治疗的剂量限制性毒性包括:2级瘤内出血(n=1)、3级斑丘疹(n=2)、3级神经系统疾病(全面性神经功能恶化)(n=1)。
  • 维持期替莫唑胺患者内剂量递增未耐受。
  • 1年总生存率为37.2%(SE 7%),2年总生存率为5.3%(SE 3%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A Pediatric Brain Tumor Consortium (PBTC) phase I/II trial of veliparib and radiation followed by veliparib and temozolomide (TMZ) was conducted in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). The objectives were to: (i) estimate the recommended phase II dose (RP2D) of veliparib with concurrent radiation; (ii) evaluate the pharmacokinetic parameters of veliparib during radiation; (iii) evaluate feasibility of intrapatient TMZ dose escalation; (iv) describe toxicities of protocol therapy; and (v) estimate the overall survival distribution compared with historical series. METHODS: Veliparib was given Monday through Friday b.i.d. during radiation followed by a 4-week rest. Patients then received veliparib at 25 mg/m2 b.i.d. and TMZ 135 mg/m2 daily for 5 days every 28 days. Intrapatient dose escalation of TMZ was investigated for patients experiencing minimal toxicity. RESULTS: Sixty-six patients (65 eligible) were enrolled. The RP2D of veliparib was 65 mg/m2 b.i.d. with radiation. Dose-limiting toxicities during radiation with veliparib therapy included: grade 2 intratumoral hemorrhage (n = 1), grade 3 maculopapular rash (n = 2), and grade 3 nervous system disorder (generalized neurologic deterioration) (n = 1). Intrapatient TMZ dose escalation during maintenance was not tolerated. Following a planned interim analysis, it was concluded that this treatment did not show a survival benefit compared with PBTC historical controls, and accrual was stopped for futility. The 1- and 2-year overall survival rates were 37.2% (SE 7%) and 5.3% (SE 3%), respectively. CONCLUSION: Addition of veliparib to radiation followed by TMZ and veliparib was tolerated but did not improve survival for patients with newly diagnosed DIPG. TRIAL REGISTRATION: NCT01514201.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Baxter PA, Su JM, Onar-Thomas A, et al. A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study. Neuro Oncol. 2020. PMID: 32009149. doi:10.1093/neuonc/noaa016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。